Adma Biologics, Inc.
ADMA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001368514
In the last 90 days, Adma Biologics, Inc. insiders filed 0 open-market purchases and 1 sale; 322 institutions reported holding it in 13F filings for Q2 2026, worth $1.70B in total; superinvestors Duquesne Family Office and Fundsmith hold it.
Key figures
- Market capClose on Nov 10, 2026
- $2.81B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $1.76M in total
- 1
- 13F holdersQ2 2026, −36 vs. previous quarter
- 322
- 13F valueReported value at the end of Q2 2026
- $1.70B
- Superinvestors holdingAt the end of Q2 2026
- 2
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $510.2M
- +19.6% year over year
- Net income, FY2025
- $146.9M
- −25.7% year over year
- Free cash flow, FY2025
- $27.8M
- −74.8% year over year
- Revenue, Q3 FY2026
- $141.1M
- +5.1% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Short interest
See short dataFrom FINRA, settlement date Oct 15, 2026.
- Short interest
- 19.5M
- Shares sold short
- Change
- −1.07M
- −5.2% vs. previous
- Days to cover
- 6.55
- At average daily volume
Superinvestors holding ADMA, Q2 2026
Go to the superinvestors tab2 superinvestors report holding Adma Biologics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Duquesne Family Office
Stanley Druckenmiller
0.5%
Adma Biologics, Inc.'s share of the portfolio
- Shares
- 2,784,110
- Value
- $23.3M
Latest insider trades
See all insider tradesOpen-market purchases and sales by Adma Biologics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 5, 2026 (view filing)9:05 PM ET | Nov 5 | Same day | Grossman Adam SPresident and CEO | SSale | −147.0K | $12.00 | −$1.76M | −6.6%2.07M after | 2 lots10b5-1 |
| May 28, 2026 (view filing) | May 27 | 1 day | Grossman Jerrold BDirector | PPurchase | +6.40K | $7.91 | +$50.6K | +1.2%520.3K after | |
| May 14, 2026 (view filing) | May 12 | 2 days | Grossman Jerrold BDirector | PPurchase | +12.5K | $8.01 | +$100.1K | +2.5%513.9K after | |
| May 12, 2026 (view filing) | May 11 | 1 day | Grossman Jerrold BDirector | PPurchase | +12.5K | $8.01 | +$100.1K | +2.6%501.4K after | |
| Mar 17, 2026 (view filing) | Mar 16 | 1 day | Grossman Adam SPresident and CEO | SSale | −21.0K | $15.16 | −$318.4K | −1.0%2.11M after | 2 lots10b5-1 |
| Mar 10, 2026 (view filing) | Mar 9 | 1 day | Kestenberg-Messina Kaitlin M.COO and SVP, Compliance | SSale | −10.1K | $15.63 | −$157.8K | −2.1%466.6K after | |
| Mar 9, 2026 (view filing) | Mar 5-6 | 4 days | Elms SteveDirector | PPurchase | +14.0K | $15.53 | +$217.4K | +0.7%2.05M after | 2 lots |
| Feb 17, 2026 (view filing) | Feb 17 | Same day | Grossman Adam SPresident and CEO | SSale | −21.0K | $16.08 | −$337.7K | −0.9%2.28M after | 2 lots10b5-1 |
| Dec 16, 2025 (view filing) | Dec 15 | 1 day | Grossman Adam SPresident and CEO | SSale | −21.0K | $19.79 | −$415.6K | −1.0%2.01M after | 2 lots10b5-1 |
| Nov 21, 2025 (view filing) | Nov 19 | 2 days | Grossman Adam SPresident and CEO | SSale | −21.0K | $16.00 | −$336.0K | −1.0%2.01M after | 2 lots10b5-1 |
Top 10 13F holders, Q2 2026
See all 322 holdersThe largest institutional positions in Adma Biologics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 38,355,684 | $321.0M | 0.00% | +1,524,910+4.1% | Added |
| State Street Corp | 17,116,022 | $143.3M | 0.00% | +3,031,817+21.5% | Added |
| Vanguard Capital Management LLC | 10,103,809 | $84.6M | 0.00% | −203,062−2.0% | Reduced |
| Vanguard Portfolio Management LLC | 10,088,490 | $84.4M | 0.00% | +1,219,833+13.8% | Added |
| Rubric Capital Management LP | 9,339,414 | $78.2M | 0.72% | +7,530,006+416.2% | Added |
| Capital Research Global Investors | 8,756,374 | $73.3M | 0.01% | −2,434,742−21.8% | Reduced |
| First Trust Advisors LP | 7,798,351 | $65.3M | 0.04% | +7,438,134+2,064.9% | Added |
| Geode Capital Management, LLC | 6,059,984 | $50.7M | 0.00% | +235,868+4.0% | Added |
| Caligan Partners LP | 5,725,007 | $47.9M | 2.31% | +968,496+20.4% | Added |
| D. E. Shaw & Co., Inc. | 5,274,597 | $44.1M | 0.03% | +4,713,770+840.5% | Added |
Holders of 5% or more of ADMA
See all 4 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Adma Biologics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 15.10%35.9M shares | – | Oct 7, 20242 filings | Apr 30, 2025 | SEC |
| State Street Corp | 13G | 7.40%17.1M shares | +2.30 ppfrom 5.10% | Oct 17, 20244 filings | Aug 7, 2026 | SEC |
| Vanguard Capital Management LLC | 13G | 5.08%12.1M shares | New | Apr 29, 20261 filing | Apr 29, 2026 | SEC |
| Invesco Ltd. | 13G/A | 5.00%11.8M shares | −0.40 ppfrom 5.40% | Nov 8, 20244 filings | Feb 12, 2026 | SEC |